VYNE Therapeutics (VYNE) Q2 2025 earnings summary

Executive summary

• Cost reductions implemented, extending cash runway into the first half of 2027.

• Pipeline focused on BET inhibitors for chronic inflammatory and immune-mediated diseases, with VYN202 and repibresib as lead candidates.

• VYN202 Phase 1b trial in psoriasis showed promising preliminary efficacy; FDA clinical hold partially lifted for female subjects, with hold for males pending additional data.

• Repibresib Phase 2b trial in vitiligo did not meet endpoints; program discontinued and seeking external partner.

Financial highlights

• Net loss of $5.8M for Q2 2025, a 38.8% improvement year-over-year; $0.13 per share.

• Cash, cash equivalents, and marketable securities totaled $39.6M as of June 30, 2025; no outstanding debt.

• Total revenues of $0.1M for Q2 2025, down 65.2% year-over-year, primarily from royalty income.

• Research and development expenses decreased 33.2% to $4.9M; general and administrative expenses down 17% to $2.7M in Q2 2025.

• Operating loss for Q2 2025: $7.5M, a 27.5% improvement year-over-year.

Outlook and guidance

• Cash runway expected to last into the first half of 2027 based on current operating assumptions.

• Additional capital will be required for further development of VYN202 and other pipeline candidates.

• Strategic review of pipeline and cost structure ongoing; seeking partners for repibresib.